Cure ATRTNov 22, 20201 minYour Child May Qualify for Disability BenefitsThe following article was written by Rachel Gaffney. If you would like additional information, you can contact Rachel at rsg@ssd-help.org.
Cure ATRTJun 2, 20201 minStanford Study on Immune Therapy Treatment of AT/RThttps://scopeblog.stanford.edu/2020/04/30/new-advances-toward-safely-targeting-immune-cells-to-pediatric-brain-tumors/
Cure ATRTJan 24, 20201 minFor Families Facing Malignant Rhabdoid Tumors, Reasons to Hope (repost from DFCI)Since 2008, Cure ATRT Now, has been funding ATRT targeted research at Dana Farber & St Jude’s hospital. This inspiring story is the...
Cure ATRTNov 6, 20171 minEpizyme Research UpdateWe continue to fight to find a cure for ATRT. This is a long & complicated fight but we are making progress, albeit slowly. This is the...
Cure ATRTDec 31, 20151 minEpizyme launches dosing programEpizyme announces first patient dosed in global clinical program. Dana Farber Cancer Institute and Cincinnati Children's Hospital are the...
Cure ATRTDec 30, 20151 minNew Research PostedNew research posted to the We Can Help -> Research section of the web site. Pitfalls in Diagnosing AT/RT: Experiences From the European...
Cure ATRT NowOct 3, 20151 minWelcome!Welcome to the new Cure ATRT Now website. When we started Cure ATRT Now, it was just a few frightened parents frustrated by the scarcity...
Cure ATRTSep 28, 20151 minEpizyme European Cancer Conference RecapThis presentation contains a lot of information, much of it very technical. The study is not specific to AT/RT, but does include AT/RT...
Cure ATRTAug 24, 20151 minFDA Accepts Drug in Phase 1 study INI1-Negative Tumors, Including AT/RTEpizyme, Inc. a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced...
Cure ATRTAug 6, 20151 minWhat is AT/RT Cancer?For those just learning about AT/RT, here is an helpful post from the Dana Farber Cancer Institute: http://blog.dana-farber.org/insight/2...
Cure ATRTNov 20, 20141 minPhase 1 Dose Escalation Shows PromiseBarcelona, Spain, November 20, 2014 – Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative...